Exposed versus nonexposed endoscopic full-thickness resection for duodenal subepithelial lesions: a tertiary care center experience (with videos).
Zaheer Nabi, Jahangeer Basha, Pradev Inavolu...
https://pubmed.ncbi.nlm.nih.gov/41647622/Actively Recruiting
Led by Ovesco Endoscopy AG · Updated on 2026-10-28
306
Participants Needed
3
Research Sites
N/A
Total Duration
This research aims to collect and analyze data from patients who have undergone endoscopic full-thickness resection EFTR in the stomach and duodenum using the gastroduodenal full-thickness resection device gdFTRD system. EFTR is a less invasive treatment option for difficult lesions such as subepithelial gastrointestinal tumors and adenomas, compared to traditional surgery. The study seeks to understand the real-world use of the gdFTRD system, confirm known risks, and identify any new complications associated with its use. The study itself does not involve performing the EFTR procedure but focuses solely on processing data from patients treated with the gdFTRD system as part of their routine care. Data collected includes physician-entered information on patient baseline characteristics, details of the procedure, any complications or adverse events, and follow-up visits. Quality checks and data management processes ensure the reliability and completeness of the collected information. Participants are adults who have already received treatment using the gdFTRD system and consented to their data being included. There are no patient-reported outcomes only medical data entered by healthcare providers is used. The main outcome measured is the technical success of the procedure immediately after it is performed, with additional evaluations of full-thickness resection, complete tumor removal, and curative resection rates within 14 days post-procedure. The study will continue collecting data until August 2030.
CONDITIONS
Gastroduodenal Full Thickness Resection Device Registry - gdFTRD® Registry
B
Bettina Stritzke
M
Marc O. Schurr, Prof. Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Ovesco Endoscopy AG
Lead Sponsor
novineon CRO GmbH
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) to confirm eligibility and consent
Duration - Up to 14 days post-procedure
Physicians enter baseline information, details of the treatment with the gdFTRD device, any complications, and follow-up visit data into the registry system.
Data entries recorded from routine care visits
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Zaheer Nabi, Jahangeer Basha, Pradev Inavolu...
https://pubmed.ncbi.nlm.nih.gov/41647622/Kaveh Hajifathalian, Yervant Ichkhanian, Qais Dawod...
https://pubmed.ncbi.nlm.nih.gov/33015330/Andreas Wannhoff, Zaheer Nabi, Leon M G Moons...
https://pubmed.ncbi.nlm.nih.gov/40079474/Benjamin Meier, Arthur Schmidt, Nicolas Glaser...
https://pubmed.ncbi.nlm.nih.gov/31187233/Ovesco Endoscopy AG
Lead Sponsor
novineon CRO GmbH
Collaborating Sponsor